RxDoctor Payments Data

Alon Steinberg, MD

Cardiovascular Disease · Ventura, CANPI 1740282862

Payments from drug & device makers

$153,998in general payments, 2019–2025

Across 747 payments — averaging $206.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$67K
  • Genentech, Inc.$58K
  • Johnson & Johnson$14K
  • Boston Scientific$4K
  • Novartis$2K
  • Amgen$2K
  • plus $8K from 43 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$14,05048%
  • Travel & lodging$9593%
  • Food & beverage$13,76447%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,998 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$980,741
Medicare patients
1,270
Services billed
6,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban491$606,830
XareltoRivaroxaban278$350,200
Repatha SureclickEvolocumab141$121,552
EntrestoSacubitril/Valsartan70$85,111
FarxigaDapagliflozin Propanediol50$63,357
JardianceEmpagliflozin26$27,429
Repatha SyringeEvolocumab17$9,228
Metoprolol Succinate628$8,670
Dabigatran EtexilateDabigatran Etexilate Mesylate15$7,522
Atorvastatin Calcium775$6,940
Valsartan286$6,600
Praluent PenAlirocumab11$5,303
Ezetimibe187$5,217
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide162$5,031
Diltiazem 24hr Er (Cd)Diltiazem Hcl92$4,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$634$606,830491 claims
Johnson & JohnsonXarelto$14,065$350,200278 claims
NovartisEntresto$1,677$85,11170 claims
AstraZenecaFarxiga$690$63,35750 claims
Boehringer IngelheimJardiance$618$27,42926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →